Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy
about
Polypoidal choroidal vasculopathy: an update on therapeutic approachesRanibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome.Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysisPracticability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy.High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian populationTwo-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients.Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.Comparison of clinical features and 3-month treatment response among three different choroidal thickness groups in polypoidal choroidal vasculopathyTwo-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.Polypoidal choroidal vasculopathy treatment options: A meta-analysis.Intravitreal ranibizumab injection combined with photodynamic therapy for polypoidal choroidal vasculopathy.Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy.[Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014]The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration
P2860
Q27006758-4FF437CD-AD94-49C2-8AEA-5FD790A753BEQ33830753-7CAA8412-BE21-4E91-81EF-BC553C0AA09EQ34718477-E4A40913-AAE4-428C-9AE6-36A3CACAEA8DQ35838315-AD3E2E49-A10C-45BA-BCB3-48CE63846C5AQ36136227-E39197F8-1E55-440C-8456-51997970AAC3Q36750280-5E8CCA5C-1C1F-478A-AD45-2F0699172918Q36787782-FBF72C9D-8CDC-45B8-8FDB-DC9A881DA9EEQ37445392-BDC06506-50B3-4146-8A27-4C206AA87A02Q41494023-72E9E575-2A3F-4747-9751-B86D94178BB5Q41763938-8B365C8F-E5B4-4D54-BA6A-7A65D500B19CQ48239027-B6ADE85C-9B7E-4ACD-BE6D-E531AB21C103Q49580624-843DC09E-C375-4C28-992F-B2E4C5CF0ED4Q50438817-72B31775-C9EE-4541-9837-925BA2E299A3Q53675303-9700BD21-083F-4739-BE05-31A818490298Q55066350-676E957F-35E3-44C9-AF36-CCF5CF9F63DDQ58766295-B0F235AC-F1BF-419A-8020-39D60502EC0F
P2860
Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Intravitreal bevacizumab and r ...... ypoidal choroidal vasculopathy
@ast
Intravitreal bevacizumab and r ...... ypoidal choroidal vasculopathy
@en
type
label
Intravitreal bevacizumab and r ...... ypoidal choroidal vasculopathy
@ast
Intravitreal bevacizumab and r ...... ypoidal choroidal vasculopathy
@en
prefLabel
Intravitreal bevacizumab and r ...... ypoidal choroidal vasculopathy
@ast
Intravitreal bevacizumab and r ...... ypoidal choroidal vasculopathy
@en
P2093
P2860
P356
P1433
P1476
Intravitreal bevacizumab and r ...... ypoidal choroidal vasculopathy
@en
P2093
P2860
P2888
P304
P356
10.1038/EYE.2011.324
P577
2011-12-16T00:00:00Z
P5875
P6179
1025328765